Pantoprazole in pediatric gastroesophageal reflux disease

Abstract

Proton-pump inhibitors (PPIs) are widely used in the treatment of gastroesophageal reflux disease, Helicobacter pylori gastritis and peptic ulcer disease. PPIs are characterized by high efficacy, safety and lack of tachyphylaxis with very selective action on the proton pump in the parietal cell. Currently, five primary PPIs are available for use in adults. Although used for similar indications in the pediatric age group, only limited data are available in children. Limited knowledge of these medications in pediatrics suggests minimal risk of short-term complications. Data are emerging on pediatric experiences with pantoprazole. Additional pharmacokinetic and clinical data are needed with this PPI, which may prove the suitability of its use in children and be used to seek pediatric labeling. A literature review of pantoprazole use in children and adolescents is presented.